Kissei stock: Buyback acquires 1.03 million shares
Published on 11/11/2026 at 01:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBuyback results and investor focus
- Kissei completed an off-market treasury-share purchase through the ToSTNeT-3 system.
- The repurchase forms part of a broader capital policy focused on capital efficiency and shareholder returns.
- Investors will continue to monitor further buybacks and the company's pharmaceutical pipeline.
Kissei Pharmaceutical completed the acquisition of 1,032,500 treasury shares on November 5, 2026, for a total price of JPY 3,877,037,500. The company used the Tokyo Stock Exchange's ToSTNeT-3 off-market tender system, according to Japan IR.
Capital policy gains a concrete result
The completed purchase brings Kissei's cumulative treasury-share acquisitions to 1,232,500 shares, with total spending of JPY 4,676,349,000. The measure is part of the company's broader effort to improve capital efficiency and support shareholder returns.
The result follows an earlier board authorization for treasury-share purchases. For investors, the next points to watch are any additional acquisitions and how the capital policy develops alongside operating conditions in Kissei's pharmaceutical business.
Kissei Pharmaceutical at a glance
- Company: Kissei Pharmaceutical Co., Ltd.
- ISIN: JP3240600001
- Ticker: 4547.T
- Business: Specialty and generic drug manufacturing
- Buyback completed: 1,032,500 shares for JPY 3,877,037,500 on November 5, 2026
Japan equities provide the broader market backdrop for Kissei stock.
